Syncom Formulations (India) Limited
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.
What Syncom files
- Others45
- Important15
- Updates9
- Board Meeting7
- Dividend/Bonus3
- Results1
Syncom Formulations has dispatched physical letters to shareholders with unregistered email addresses, providing web-links to access the Annual Report and the notice for the upcoming 38th Annual General Meeting. Shareholders can also request physical copies by writing to the company.
Syncom Formulations (India) Limited has submitted its Business Responsibility and Sustainability Report for the financial year. This filing highlights the company's ongoing commitment to transparent environmental, social, and governance practices, keeping investors updated on its core operational responsibility metrics.
Syncom Formulations reported strong Q1 results: total income rose 8% to ₹133.36 Cr, and PAT surged 58% to ₹24.85 Cr. The Board proposes a ₹0.10 per share final dividend for FY26. Growth is driven by its ethical, prescription-led model and expanding market presence.
$SYNCOMF: Syncom Formulations will offer remote e-voting for its upcoming Annual General Meeting. This move enhances shareholder participation and accessibility, allowing investors to conveniently cast their votes electronically. A step towards improved corporate governance.
SYNCOM FORMULATIONS has submitted its promoters' yearly shareholding disclosures, including those from Persons Acting in Concert, to the exchanges. This update ensures transparency on their holdings.